No. 5 / 2025Zealand Pharma increases its share capital as a result of the exercise of employee warrantsCopenhagen, ...

Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The ...

Copenhagen, Denmark, March 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide ...

Investing.com -- Morgan Stanley (NYSE: MS) upgraded its rating on Zealand Pharma (NASDAQ: ZEAL) shares to Overweight from ...

Copenhagen, Denmark, March 20, 2025 - Zealand Pharma A/S ("Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

COPENHAGEN - Zealand Pharma A/S (NASDAQ:ZEAL), a Danish biotechnology firm with a market capitalization of $5.8 billion, has announced a nominal increase to its share capital following the ...

COPENHAGEN - Zealand Pharma A/S (NASDAQ:ZEAL), a Danish biotechnology firm with a market capitalization of $5.8 billion, has announced a nominal increase to its share capital following the exercise of ...

Zealand Pharma remains on track to initiate the Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes in the first half of 2025. Copenhagen, Denmark, March ...

For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal ...

Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday. A total of 106 patients with ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.